Bristol Myers Squibb Q3 2026 Results: Growth Portfolio Now 59% of Sales as Eliquis Cliff Nears
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as the Growth Portfolio hits 59% of sales. The Eliquis cliff explained.
Tag: pharmaceutical industry earnings
Read More